



Bayer-THU Collaboration

Call for Application

2025 Bayer Microfunding

Collaborate to Cure Hub China
Bayer Pharmaceuticals

拜耳处方药中国合作创新中心

Dec 2025



RESTRICTED

Introduction

About Bayer Microfunding

To encourage research translation in drug discovery, Bayer will support Tsinghua in three **Microfunding** projects by an aggregate amount of up to 1.2 million CNY per year.

- // Each Microfunding project can be funded with up to a total of 400 kCNY for a maximum duration of two years
- // Microfunding projects will be research projects in Bayer's interested area, the projects will be solely conducted by Tsinghua investigators without involvement of Bayer. However, Bayer will try the best if any support is needed
- // The funding is to support Tsinghua Investigators to freely explore innovation translation, therefore, any project results deriving from a Microfunding project will solely be owned by Tsinghua

Who May Apply?

- // Eligible applicants need to be full-time employees of Tsinghua at the time of applying and receiving the fund
- // Working in the School of Life Sciences, Tsinghua Medicine, Department of Chemistry, or School of Information Science and Technology of Tsinghua
- // Independent of having a project with Bayer or not
- // **Must not** be healthcare professionals, or employed by a hospital due to international compliance requirements
- // Members of the Joint Steering Committee (JSC) may not apply for the fund
- // Having clear path of translating their research



Evaluation Process

- // The proposal will be evaluated based on the following considerations:
 1. Feasibility of translating your research to drug discovery
 2. Innovation and breakthrough potential in solving current unmet needs in diseases and drug discovery
 3. Research relevance to Bayer's areas of interest, including:
 - // **Therapeutic areas** in **Precision Oncology** (e.g. precision drug development (PDD) approach: having a deep understanding of the target to disease link in defined patient populations, where modulating target biology with a fit for purpose modality will create measurable impact. Tumor types in focus: GI (CRC, HCC, gastric), GU (prostate, bladder, RCC), lung cancer), **Precision cardiorenal diseases** (e.g. Heart Failure, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease), **Neurology & Rare diseases** enabled by cell and gene therapy, **Immunology & Inflammation** (e.g. SLE, IBD), and **Radiology** Molecular imaging tracers.
 - // **Novel technologies/platforms** that enable target identification/entry into druggability, specifically: Interactome analysis, methods for identification of new allosteric pockets and binders, multi-omics techniques, structural biology and biophysical methods (e.g. X-Ray, cryo-EM, AS MS, NMR, etc.), bioinformatics. Acceleration of learning cycles: Organ on chip to accelerate insights generation for new targets and cps, prediction/ data science aspects specifically for acceleration of learning cycles, ML & AI. Formulation technologies, targeted drug delivery: e.g. organ specific LNPs, etc. Screening technologies, HTS, DEL, imaging technologies, phenotypic screens. Automated chemistry, direct to biology (D2B) approaches
 - // **Therapeutic modalities** Small molecules and non-traditional SMOLs (such as covalent binders, molecular glues, protein degraders, RNA binders, fragments, bRo5), peptides, therapeutic antibodies, targeted radiotherapeutics, conjugated modalities in general (antibody, peptide, glyco, radio), antisense and siRNA therapeutics
- // The proposal provided will be evaluated by Bayer scientific experts and the Joint Steering Committee (JSC) from both Bayer and Tsinghua University
- // Decision Letter will be sent out in **March 2026**. Bayer Alliance Manager will contact you regarding the decision and discuss the next steps.



Obligation

// Use of Microfunding:

- // The Microfunding shall be used exclusively for the performance of the Microfunding projects
- // Microfunding cannot be used to fund equipment and infrastructure.

// Recipients of Bayer Microfunding Shall:

- // Provide a mid-term and final report to Bayer for the project progress
- // Acknowledge funding by Bayer in their talks and publications in related areas of interest



Submission Process

// Submit your proposal by **Jan 30th, 2026**

- // Please use the Application Form to submit an abstract of your research proposal or technology
- // Please indicate in the abstract :
 - // What unmet need your research addresses?
 - // What is the advantage/differentiation of your solution?
 - // IP situation
 - // Path forward for the translation of your research

// Please note that only **non-confidential information should be provided**

// Submit your proposal to Bayer and Tsinghua Alliance Managers

Duan Wang (王端)

Collaborate to Cure Hub China
Bayer Pharmaceuticals

Mobile: +86 18221448381
E-mail: duan.wang@bayer.com

Yuxin Li (李玉鑫)

Biomedical Innovation Office
Tsinghua University

Tel: +86 10 6278 1816
Mobile: +86 13848615270
E-mail: yuxin-li@mail.tsinghua.edu.cn

||||| *Health for all, Hunger for none*



Thank
you!